UNIGE document Scientific Article
previous document  unige:124239  next document
add to browser collection
Title

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis

Authors
Back, David
Belperio, Pamela
Bondin, Mark
Talal, Andrew H
Park, Caroline
Zhang, ZhenZhen
Pinsky, Brett
show hidden authors show all authors [1 - 11]
Published in Journal of Viral Hepatitis. 2019, vol. 26, no. 8, p. 951-960
Abstract Although direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection are highly efficacious and safe, treatment initiation is often limited in patients with neuropsychiatric disorders due to concerns over reduced treatment adherence and drug-drug interactions. Here, we report adherence, efficacy, safety and patient-reported outcomes (PROs) from an integrated analysis of registrational studies using the pangenotypic DAA regimen of glecaprevir and pibrentasvir (G/P). Patients with chronic HCV genotypes 1-6 infection with compensated liver disease (with or without cirrhosis) receiving G/P for 8, 12 or 16 weeks were included in this analysis. Patients were classified as having a psychiatric disorder based on medical history and/or co-medications. Primary analyses assessed treatment adherence, efficacy (sustained virologic response at post-treatment week 12; SVR12), safety and PROs. Among 2522 patients receiving G/P, 789 (31%) had a psychiatric disorder with the most common diagnoses being depression (64%; 506/789) and anxiety disorders (27%; 216/789). Treatment adherence was comparably high (>95%) in patients with and without psychiatric disorders. SVR12 rates were 97.3% (768/789; 95% CI = 96.2-98.5) and 97.5% (1689/1733; 95% CI = 96.7-98.2) in patients with and without psychiatric disorders, respectively. Among patients with psychiatric disorders, SVR12 rates remained >96% by individual psychiatric diagnoses and co-medication classes. Overall, most adverse events (AEs) were mild-to-moderate in severity with serious AEs and AEs leading to G/P discontinuation occurring at similarly low rates in both patient populations. In conclusion, G/P treatment was highly efficacious, well-tolerated and demonstrated high adherence rates in patients with chronic HCV infection and psychiatric disorders.
Identifiers
PMID: 30977945
Full text
Article (Published version) (583 Kb) - public document Free access
Structures
Research group Etudes et traitement de l'hépatite C et B (554)
Citation
(ISO format)
BACK, David et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis. In: Journal of Viral Hepatitis, 2019, vol. 26, n° 8, p. 951-960. https://archive-ouverte.unige.ch/unige:124239

14 hits

0 download

Update

Deposited on : 2019-10-10

Export document
Format :
Citation style :